A Prospective Study to Compare the Glycemic Control of An Individual with Type 2 Diabetes Mellitus After Adding an SGLT2 Inhibitor to Therapy.

Abstract

Background & Methods: The aim of the study is to compare the glycemic control of an individual with Type 2 Diabetes Mellitus after adding an SGLT2 inhibitor to therapy. Study will include the patients admitted at Jaslok Hospital and Research Centre or patients coming to Jaslok Hospital and Research Center OPD. We stratified patients based on baseline HbA1c into 3 categories; HbA1c <8%, HbA1c 8-10 % and > 10 %. Number of patients in each category was respectively observed to be 19 patients (22.4%), 46 patients (54.1 %) and 20 patients (23.5 %) on enrolment. It was observed that majority of patients had HbA1c between 8-10 %. Baseline anti- diabetic therapy of all these patients included metformin and a DPP4 inhibitor. An SGLT2 inhibitor was then added to the treatment of diabetes and change in HbA1c at the end of 6 months was observed.

Conclusion: Maximum number of Diabetic Patients belonged to the age group of 46-55 years in the group. Mean Age of the study population was found to be 53.27 years. 58.8% i.e., 50 patients were males in the study group and 41.2 % i.e., 35 patients were females. It was observed that there was a significant reduction in HbA1c with the drug over a period of 6 months. It was also observed that more the initial Hba1c, more is the reduction in Hba1c. The Clinical Prospective Follow-up study conducted at Jaslok Hospital and Research Centre shows that SGLT2 inhibitors, help in improving not only blood sugar control in Diabetics but also have significant positive outcomes in various other Clinical, Biochemical and metabolic parameters.